
ABSTRACT Aging‐associated masseter degeneration contributes to oral functional decline, but its underlying mechanisms remain incompletely understood. We investigated whether the inorganic anion nitrate protects the masseter through Sialin‐dependent mitochondrial regulation. Submandibular duct ligation was associated with reduced masseter nitrate levels and increased senescence‐ and atrophy‐associated markers, while nitrate deprivation induced senescence‐associated dysfunction in cultured myogenic cells. Nitrate supplementation attenuated degenerative changes in naturally aged and D‐galactose‐treated masseter muscle and preserved the morphology of differentiated C2C12 myotubes. Sialin depletion impaired cellular bioenergetic function and attenuated the response to nitrate. Multi‐omics and functional analyses linked Sialin deficiency to altered mitochondrial architecture, reduced respiratory‐chain subunit abundance, lower oxygen‐consumption readouts and ATP content, and increased oxidative stress. Nitrate increased NDUFS1 protein abundance without a detectable change in transcript levels and slowed NDUFS1 loss during cycloheximide chase. These changes were accompanied by reduced K48‐linked ubiquitin signal in NDUFS1 immunoprecipitates. Protein‐binding and proximity assays supported a model linking nitrate‐responsive NDUFS1 turnover to Sialin‐dependent USP48‐NDUFS1 association. In vivo, Myf5‐Cre‐mediated Slc17a5 deletion caused masseter abnormalities that were not significantly improved by nitrate, whereas MitoQ attenuated several tissue phenotypes. Together, these findings identify a Sialin‐dependent protective response to nitrate in aging‐associated masseter degeneration and implicate NDUFS1 proteostasis as a candidate mechanism linking inorganic anion signaling to mitochondrial homeostasis.
ABSTRACT Vascular aging (VA) contributes to the development of aging‐associated vascular diseases. Endothelial senescence, inflammation, and mitochondrial dysfunction are hallmarks of VA. Asprosin (ASP), a newly discovered adipokine, has been shown to adversely affect mitochondrial homeostasis, inflammation, and vascular endothelial function. However, it is unclear whether and how ASP affects VA. Gene expression profile related to VA (GSE45540) shows an upregulation of FBN1 which encodes ASP in human microvascular endothelial cells, and serum ASP levels are positively correlated with age in mice. Moreover, ASP accelerates the aging process and exacerbates vascular endothelial dysfunction. Conversely, either adipose tissue‐specific ASP deficiency (ASP −/− ) or ASP antibody (AASP) intervention significantly attenuates the aging process and vascular endothelial dysfunction in aging mice. Besides, ASP treatment induces mitochondrial oxidative stress, mitochondrial DNA (mtDNA) leakage, and STING pathway activation in human umbilical vein endothelial cells (HUVECs). Downregulation of STING alleviates the senescence of HUVECs. Moreover, suppression of mitochondrial ROS (mtROS) with mitoTEMPO reduces mtDNA leakage and STING activation, thereby attenuating HUVEC senescence. Furthermore, VA is an important risk factor for atherosclerosis (AS). Our results show that ASP −/− alleviates AS in ApoE −/− mice fed with HFD. Together, these findings suggest that ASP accelerates VA via a mtROS‐dependent mechanism, which promotes mtDNA leakage and activates the cytosolic STING pathway. Additionally, ASP −/− mitigates AS in ApoE −/− mice. The findings highlight that ASP is a pro‐aging risk factor and would be a potential intervention target for aging‐associated vascular diseases such as AS.
ABSTRACT Aging research has increasingly recognized the need for accurate biomarkers of aging, with aging clocks emerging as a powerful tool to quantify the degree of age‐related biological change. However, broad clinical implementation and the establishment of wide use of these biomarkers of aging remain ongoing. Resilience reflects a dynamic property of physiological homeostasis and offers a complementary lens to functionally interpret aging. Resilience does not capture the ground state the biological system is in, but rather its ability to maintain or improve function when challenged by adversity. Advances in wearable sensing technologies now enable scalable, continuous, and laboratory‐independent assessment of physiological, biochemical, and environmental parameters, which potentially offer a first window into resilience. Clinically, resilience holds promise for person‐centered risk stratification and guiding interventions, particularly in multimorbid populations. As such, we propose two lines of clinical resilience: first, reflecting involvement in disease onset mechanisms, and a second representing the capability to withstand and recover from medical interventions such as surgery or systemic pharmacotherapy. Integrating resilience into clinical frameworks may support personalized, proactive, and preventive approaches to aging, ultimately leading to meaningful clinical outcomes.
ABSTRACT The ability to recover skeletal muscle after periods of disuse declines with age leading to persistent deficits in strength and function that extend beyond muscle mass loss. Here, we investigated whether age‐related alterations in lipid remodeling contribute to impairment in skeletal muscle recovery following disuse. Lipidomic and oxylipin profiling revealed that aged mouse muscle is characterized by sustained phosphatidylcholine and omega‐6‐dependent COX‐prostaglandin signaling during early recovery from disuse atrophy. This persistent lipid mediator response was associated with increased senescence burden, fibrosis, and impaired functional recovery. Pharmacological suppression of COX signaling during reloading in aged mice reduced senescence markers, limited fibrosis, and improved muscle function independent of improved muscle size. Mechanistically, senescent induced macrophages produced COX‐2‐dependent PGE2 and impaired myotube size and fusion through paracrine signaling. Activation of EP2 signaling was sufficient to induce a senescent macrophage phenotype. Importantly, a similar age‐associated dysregulation of oxylipin content was observed in older adults after limb immobilization, supporting the translational relevance of these findings. Together, our results identify sustained COX‐prostaglandin signaling as a key feature of impaired skeletal muscle recovery with aging and suggest that targeted modulation of this pathway may improve muscle recovery in older individuals. Trial Registration: ClinicalTrials.gov identifier: NCT04416191
ABSTRACT Aging research has advanced along two largely parallel paths. Experimental biology has transformed aging research by establishing that aging is biologically malleable and identifying conserved molecular and cellular mechanisms that regulate lifespan and healthspan. In parallel, population research has revealed substantial heterogeneity in human aging and identified social, environmental, behavioral, and genetic factors associated with differences in aging trajectories. Despite a shared goal of extending healthy aging, limited integration between these fields constrains progress. We argue that building upon these complementary advances and increasing greater integration between experimental biology and population approaches, termed convergent geroscience , can further accelerate the field. We highlight examples of this integration, including biological aging clocks that provide measurable readouts associated with social exposures and molecular processes, population‐informed model systems that incorporate heterogeneity, and population‐derived findings that catalyze mechanistic discovery. We further discuss how incorporating variability, context, and real‐world complexity into experimental design can improve translational relevance. Finally, we propose priorities for advancing this integrative framework. Convergent geroscience offers a path toward more effective, equitable interventions that can extend healthspan at scale.